Collaboration with ISC Clause Samples

Collaboration with ISC. Collaboration between the applicant and the ISC is a requirement of this award. Failure of the applicant to accept the guidance of the ISC may be the basis for the termination of this award. Pursuant to the Grant agreement ▇▇▇▇-▇▇▇▇▇▇▇▇▇▇ Scholars will, at the start of funding, meet with the members of the HDI ISC to define and agree upon a development-oriented, milestone-based program and budget. Specifically, direct funding support will be milestone-driven, contingent on development progress and ongoing engagement with the ISC. Either FFB or HDI may provide additional direct support during the course of the project, at their discretion. Follow on funding by HDI will require that ▇▇▇▇-▇▇▇▇▇▇▇▇▇▇ Scholars follow HDI procedures, including formal recommendation by the ISC and approval of the ▇▇▇▇▇▇▇▇▇▇ Project Investment Advisory Board (the “IAB”) consistent with the Grant agreement. Through the duration of the Grant agreement, HDI will provide the Center awardees with the following: • Access to ISC-supported consultants with significant industry experience • A person or team from the ISC assigned to each awardee to provide active project guidance/management • Analysis of IP strategy • Commercial and Market assessment • Consideration for supplementary HDI/ISC funds, subject to an additional signed written agreement between the parties and a ▇▇▇▇-▇▇▇▇▇▇▇▇▇▇ Scholar’s institution. • Facilitated access to strategic investment and commercial partners for future development ISC support also includes facilitated access to an ISC/institutional consortium and resources including Contract Research Organizations (“CROs”) and academic drug discovery centers that can provide: • High throughput screening (“HTS”) including screen development • Medicinal chemistry • Preclinical development including toxicology, safety pharmacology, and Drug Metabolism and Pharmacokinetics (“DMPK”) • Pharmaceutical development including formulation